Detalhe da pesquisa
1.
Primary brain tumours in adults.
Lancet
; 402(10412): 1564-1579, 2023 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738997
2.
Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Eur J Nucl Med Mol Imaging
; 50(4): 1195-1204, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454268
3.
MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
J Neurooncol
; 152(2): 357-362, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33611761
4.
The Role of Rituximab in Primary Central Nervous System Lymphoma.
Curr Oncol Rep
; 22(8): 78, 2020 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602069
5.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol
; 20(2): 216-228, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30630772
6.
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.
Hematol Oncol
; 37(5): 548-557, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31418878
7.
Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.
Lancet Oncol
; 19(8): e407-e418, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30102235
8.
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Hematol Oncol
; 35(4): 497-503, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27530779
9.
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol
; 17(11): 1533-1542, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686943
10.
Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands.
Haematologica
; 106(2): 597-600, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32241841
11.
Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.
Cerebellum
; 14(6): 642-9, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25728839
12.
Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
J Neurooncol
; 121(2): 365-72, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25344884
13.
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Lancet Oncol
; 15(9): 943-53, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25035291
14.
MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
Br J Haematol
; 185(5): 974-977, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408153
15.
Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes.
Neuropathol Appl Neurobiol
; 45(3): 318-323, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29679382
16.
Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.
Haematologica
; 99(7): 1228-35, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24727817
17.
Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study.
BMC Neurol
; 14: 157, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25124385
18.
Primary central nervous system lymphoma.
J Neurol
; 271(5): 2906-2913, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38112784
19.
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review.
Neuro Oncol
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598668
20.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Neuro Oncol
; 26(4): 724-734, 2024 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38037691